These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23623323)

  • 1. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
    Kibria G; Hatakeyama H; Sato Y; Harashima H
    Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
    Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
    J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
    J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    J Control Release; 2011 Jul; 153(2):141-8. PubMed ID: 21447361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide.
    Zhang Q; Lu L; Zhang L; Shi K; Cun X; Yang Y; Liu Y; Gao H; He Q
    Sci Rep; 2016 Feb; 6():19800. PubMed ID: 26842655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
    Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
    Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
    Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
    Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.
    Biswas S; Dodwadkar NS; Deshpande PP; Parab S; Torchilin VP
    Eur J Pharm Biopharm; 2013 Aug; 84(3):517-25. PubMed ID: 23333899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming.
    Tan X; Fang Y; Ren Y; Li Y; Wu P; Yang X; Liu W
    Int J Nanomedicine; 2019; 14():1255-1268. PubMed ID: 30863058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
    Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects.
    Song Z; Lin Y; Zhang X; Feng C; Lu Y; Gao Y; Dong C
    Int J Nanomedicine; 2017; 12():1941-1958. PubMed ID: 28331317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined integrin α
    Qi N; Zhang S; Zhou X; Duan W; Gao D; Feng J; Li A
    J Nanobiotechnology; 2021 Dec; 19(1):446. PubMed ID: 34949198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
    Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
    Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
    Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
    J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
    He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
    Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
    Ara MN; Matsuda T; Hyodo M; Sakurai Y; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials; 2014 Aug; 35(25):7110-20. PubMed ID: 24875764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.